Efthymios Deliargyris
Chief Tech/Sci/R&D Officer at CYTOSORBENTS CORPORATION
Net worth: 388 961 $ as of 2024-03-30
Profile
Efthymios N.
Deliargyris is currently the Chief Medical Officer at CytoSorbents Corp.
He previously held the same position at PLx Pharma, Inc. from 2018 to 2020.
Prior to that, he was the Director of Cardiology and Interventional Cardiology at Athens Medical Center SA from 2004 to 2010, and an Assistant Professor at Wake Forest University from 2001 to 2004.
Deliargyris earned a doctorate degree from the National & Kapodistrian University of Athens.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CYTOSORBENTS CORPORATION
0.78% | 2024-04-01 | 409,433 ( 0.78% ) | 388 961 $ | 2024-03-30 |
Efthymios Deliargyris active positions
| Companies | Position | Start |
|---|---|---|
| CYTOSORBENTS CORPORATION | Chief Tech/Sci/R&D Officer | 2020-04-30 |
Former positions of Efthymios Deliargyris
| Companies | Position | End |
|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Chief Tech/Sci/R&D Officer | 2020-04-29 |
| ATHENS MEDICAL C.S.A. | Corporate Officer/Principal | 2009-12-31 |
| Wake Forest University | Corporate Officer/Principal | 2003-12-31 |
Training of Efthymios Deliargyris
| National & Kapodistrian University of Athens | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ATHENS MEDICAL C.S.A. | Health Services |
| CYTOSORBENTS CORPORATION | Health Technology |
| Private companies | 1 |
|---|---|
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
- Stock Market
- Insiders
- Efthymios Deliargyris
